Seizure · 2026
GLP-1 receptor agonists in people with epilepsy: A scoping review of clinical data, safety, and therapeutic implications.
СтатьяScoping ReviewНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pinto Lecio Figueira, Guerreiro Carlos Alberto Mantovani
Аннотация
PURPOSE: People with epilepsy (PWE) carry a disproportionate burden of type 2 diabetes mellitus, obesity, and cardiovascular disease, conditions for which glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed. As the use of these agents expands, neurologists are more frequently involved in the care of patients receiving GLP-1-based therapies. We reviewed current evidence regarding the neurologic safety, pharmacokinetic considerations, and potential clinical implications of GLP-1 RAs in PWE.
METHODS: We conducted a scoping review following PRISMA-ScR principles of preclinical studies, observational cohorts, meta-analyses, and pharmacokinetic reports evaluating GLP-1 RA use in relation to seizures, epilepsy outcomes, antiseizure medication interactions (ASMs), and safety.
RESULTS: Preclinical studies consistently suggest antiseizure and neuroprotective effects mediated through modulation of neuroinflammation, oxidative stress, and neuronal survival pathways. In human populations, large observational cohorts and meta-analyses have associated GLP-1 RA use with lower risks of incident seizures, reduced seizure recurrence, and fewer severe outcomes, including status epilepticus and hospitalization, with relative risk reductions ranging from approximately 10% to 57% across studies. GLP-1 RAs delay gastric emptying and may alter the timing of ASMs absorption; however, overall drug exposure appears largely unchanged in most cases. Available clinical and pharmacovigilance data do not indicate increased risks of seizure worsening or major neuropsychiatric adverse events.
CONCLUSION: Current evidence suggests that GLP-1 RAs are generally safe and clinically relevant in appropriately selected PWE, with potential benefits extending beyond metabolic control. Because available human data remain largely observational, prospective epilepsy-specific studies are needed to clarify their long-term neurologic impact.
METHODS: We conducted a scoping review following PRISMA-ScR principles of preclinical studies, observational cohorts, meta-analyses, and pharmacokinetic reports evaluating GLP-1 RA use in relation to seizures, epilepsy outcomes, antiseizure medication interactions (ASMs), and safety.
RESULTS: Preclinical studies consistently suggest antiseizure and neuroprotective effects mediated through modulation of neuroinflammation, oxidative stress, and neuronal survival pathways. In human populations, large observational cohorts and meta-analyses have associated GLP-1 RA use with lower risks of incident seizures, reduced seizure recurrence, and fewer severe outcomes, including status epilepticus and hospitalization, with relative risk reductions ranging from approximately 10% to 57% across studies. GLP-1 RAs delay gastric emptying and may alter the timing of ASMs absorption; however, overall drug exposure appears largely unchanged in most cases. Available clinical and pharmacovigilance data do not indicate increased risks of seizure worsening or major neuropsychiatric adverse events.
CONCLUSION: Current evidence suggests that GLP-1 RAs are generally safe and clinically relevant in appropriately selected PWE, with potential benefits extending beyond metabolic control. Because available human data remain largely observational, prospective epilepsy-specific studies are needed to clarify their long-term neurologic impact.